新股速遞 | 科濟藥業-B一手入場費16565.26港元,乙頭門檻約662.61萬港元,引入禮來、睿遠、南方基金等9名基石
uSMART盈立智投6月7日消息,科濟藥業-B今日起招股,一手入場費16565.26港元,引入9名基石投資者,按上限定價計,合共鎖定57.44%的發行股份。
科濟藥業-B是一家在中國及美國擁有業務的生物製藥公司,專注於治療血液惡性腫瘤和實體瘤的創新CAR-T細胞療法。
招股信息
(1)簡稱及代碼:科濟藥業-B,2171.HK
(2)招股日期:6月7日-10日
公佈中籤日:6月17日
上市日期:6月18日
計息日:7天
(3)發售價:29.6港元-32.8港元
(4)入場費:每手500股,一手入場費16,565.26港元,乙頭需申購20萬股,金額約662.61萬港元

(5)發行股數:94,747,000股(10%香港公開發售,90%國際發售)
(6)集資金額:28.05億-31.08億港元
(7)市值:167.93億-186.09億港元
(8)保薦人:高盛、瑞銀
(9)基石投資者(9名):LAV(禮來) 、新華資本、CloudAlpha、睿遠、WT、廣發基金、Dymon Asia、常春藤、南方基金,按上限定價計,合共鎖定57.44%的發行股份

(10)回撥機制:常規回撥
公開認購倍數爲15倍或以上但少於50倍,公開發售比例從10%提升至30%
公開認購倍數爲50倍或以上但少於100倍,公開發售比例從10%提升至40%
公開認購倍數爲100倍或以上,公開發售比例從10%提升至50%
(11)中籤率預測
目前打新市場情緒回溫,最大比例回撥或是大概率事件,屆時,公開發售股數爲47,373,500股,共94747手,甲乙組分別約47373手,按25-45萬人申購,一手中籤率或爲5%-10%。
點擊可閱讀《科濟藥業-B招股書》
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.